Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling studyResearch in context

• Главные авторы: Caroline Cândida Carvalho de Oliveira (Автор), Leandro Barile Agati (Автор), Camilla Moreira Ribeiro (Автор), Valéria Cristina Resende Aguiar (Автор), Roberto Augusto Caffaro (Автор), Marisa da Silva Santos (Автор), Ricardo Ribeiro Alves Fernandes (Автор), Carlos Alberto da Silva Magliano (Автор), Alfonso Tafur (Автор), Alex C. Spyropoulos (Автор), Renato Delascio Lopes (Автор), Jawed Fareed (Автор), Eduardo Ramacciotti (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2023-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Summary: Background: In patients at high risk of thromboembolism who were discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days significantly improved clinical outcomes, reducing thrombotic events compared with no post-discharge anticoagulation....